VYCOR MEDICAL, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.9M | $1.6M | $1.5M | $1.2M | $1.4M | $1.1M | $1.4M |
| Cost of Revenue | — | $302.3K | $166.8K | $145.0K | $140.6K | $134.7K | $132.5K | $134.8K |
| Gross Profit | — | $1.6M | $1.4M | $1.3M | $1.1M | $1.3M | $1.0M | $1.3M |
| Gross Margin | — | 83.8% | 89.5% | 90.1% | 88.5% | 90.3% | 88.4% | 90.3% |
| Operating Expenses | ||||||||
| Research & Development | — | $10.0K | $15.3K | $22.6K | — | $15.2K | $0 | $0 |
| SG&A Expense | — | $1.5M | $1.4M | $1.2M | $1.3M | $1.6M | $1.7M | $1.8M |
| Operating Income | — | $33.9K | $-9.1K | $40.2K | $-306.5K | $-436.0K | $-727.4K | $-601.4K |
| Operating Margin | — | 1.8% | -0.6% | 2.8% | -25.1% | -31.3% | -63.7% | -43.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-70.2K | $-107.0K | $-63.1K | $-399.7K | $-408.2K | $-800.3K | $-670.2K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-72.4K | $-107.2K | $-69.7K | $-404.9K | $-435.7K | $-822.5K | $-796.2K |
| Net Margin | — | -3.9% | -6.7% | -4.8% | -33.1% | -31.3% | -72.0% | -57.2% |
| EPS (Basic) | — | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.05 |
| EPS (Diluted) | — | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.05 |
| Shares Outstanding (Basic) | 33.4M | 33.4M | 32.9M | 32.6M | 31.7M | 29.6M | 27.4M | 25.3M |
| Shares Outstanding (Diluted) | 33.4M | 33.4M | 32.9M | 32.6M | 31.7M | 29.6M | 27.4M | 25.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |